The Safety of Atomoxetine for the Treatment of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Comprehensive Review of Over a Decade of Research
Crossref DOI link: https://doi.org/10.1007/s40263-016-0349-0
Published Online: 2016-06-11
Published Print: 2016-07
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Reed, Victoria A.
Buitelaar, Jan K.
Anand, Ernie
Day, Kathleen Ann
Treuer, Tamás
Upadhyaya, Himanshu P.
Coghill, David R.
Kryzhanovskaya, Ludmila A.
Savill, Nicola C.
Funding for this research was provided by:
Eli Lilly and Company
License valid from 2016-06-11